Use of an anti-cd2 antibody drug conjugate (adc) in allogeneic cell therapy
AssigneeMagenta Therapeutics, Inc.
InventorsAnthony Boitano, Michael Cooke
Life of this patent
Estimating the term…
Abstract
The invention provides methods of depleting CD2+ cells in human patients undergoing chimeric antigen receptor (CAR) immunotherapy in order to promote acceptance of CAR expressing immune cells. Anti-CD2 antibody drug conjugates (ADCs) are administered as a conditioning regimen to a human patient receiving autologous or allogeneic CAR expressing immune cells such that the CAR expressing immune cells are accepted by the human patient. Compositions and methods of the invention can be used in combination with CAR therapy to treat a variety of pathologies, including autoimmune diseases and cancer.
Claims36
A method of promoting acceptance of an immune cell expressing a chimeric antigen receptor (CAR) in a human subject having cancer or an autoimmune disease, the method comprising
- (a) administering an anti-CD2 antibody drug conjugate (ADC) to a human subject having cancer or an autoimmune disease, wherein the anti-CD2 ADC comprises an anti-CD2 antibody, or antigen-binding fragment thereof, conjugated to a cytotoxin via a linker;
- and
- (b) administering a therapeutically effective amount of an immune cell expressing a CAR to the human subject, wherein the CAR comprises an extracellular domain that binds to a tumor antigen or an antigen associated with an autoimmune disease, a transmembrane domain, and a cytoplasmic domain.
(canceled)
(canceled)
(canceled)
A method of treating a patient having a tumor comprising (i) an anti-CD2 ADC, wherein the anti-CD2 ADC comprises an anti-CD2 antibody, or antigen-binding fragment thereof, conjugated to a cytotoxin via a linker, and (ii) administering to the patient a therapeutically effective amount of from about 1×106 to about 1×108 engineered CAR T cells/kg.
(canceled)
-15. (canceled)
-19. (canceled)
(canceled)
-28. (canceled)
(canceled)
Dependencies are inferred from the claim text.